Welcome to our dedicated page for Alector news (Ticker: ALEC), a resource for investors and traders seeking the latest updates and insights on Alector stock.
Alector, Inc. (Nasdaq: ALEC) is a clinical-stage biotechnology company headquartered in South San Francisco, California, pioneering a novel therapeutic approach known as immuno-neurology. The company leverages the body’s innate immune system to develop treatments for neurodegenerative diseases, including Alzheimer’s disease and frontotemporal dementia (FTD). Alector’s groundbreaking research focuses on counteracting brain pathologies by restoring healthy immune function.
The company’s pipeline includes several promising product candidates like AL001 (latozinemab), AL002, AL003, and AL101. Among these, latozinemab and AL101 are being co-developed in collaboration with global biopharmaceutical giant GSK. Latozinemab, a progranulin-elevating monoclonal antibody, is currently in the pivotal Phase 3 INFRONT-3 trial for FTD-GRN and has received FDA Breakthrough Therapy and Fast Track designations.
AL002, in collaboration with AbbVie, is a TREM2-activating antibody undergoing a Phase 2 INVOKE-2 trial to assess its efficacy in early Alzheimer's disease. The company recently completed enrollment for INVOKE-2, with a data readout expected in the fourth quarter of 2024. AL101, another progranulin-elevating candidate, has initiated the PROGRESS-AD Phase 2 trial to treat early Alzheimer's disease.
Alector’s innovative Alector Brain Carrier (ABC) technology aims to enhance drug delivery across the blood-brain barrier, further strengthening their therapeutic pipeline. The company’s financial health is robust, with $620.0 million in cash, cash equivalents, and investments as of January 2024. This financial buffer is anticipated to fund operations through 2026, ensuring continued progress in their clinical programs.
For ongoing updates and detailed information, visit their official website at www.alector.com.
Alector, a clinical-stage biotechnology firm focused on immuno-neurology, announced its participation in two investor conferences. Firstly, at the Cowen 43rd Annual Health Care Conference in Boston on March 7, 2023, where management will be part of a panel at 10:30 a.m. ET. Secondly, they will engage in a fireside chat during the Stifel 2023 CNS Days virtually on March 28, 2023, at 12:00 p.m. ET. Webcasts for both events will be available on Alector's website, with replays accessible for 30 and 90 days respectively.
Alector is dedicated to developing therapies for neurodegenerative diseases, targeting immune dysfunction linked to conditions like Alzheimer’s and frontotemporal dementia.
Alector, a clinical-stage biotechnology firm, reported its financial results for Q4 and full year 2022, highlighting a cash position of $712.9 million sufficient to fund operations through 2025. The company is nearing completion of enrollment in the INVOKE-2 Phase 2 trial for AL002 in early Alzheimer’s disease, with data expected by Q4 2024. Collaboration revenue for 2022 was $133.6 million, down from $207.1 million in 2021, primarily due to prior year's income from the GSK agreement. R&D expenses rose to $210.4 million in 2022. Alector anticipates collaboration revenue between $15 million and $25 million for 2023.
Alector, Inc. (Nasdaq: ALEC) announced on December 6, 2022, that it granted stock options and restricted stock units (RSUs) to eight new employees. The awards included options to purchase 91,851 shares of common stock at an exercise price of $9.27 per share and RSUs for 40,961 shares. These grants are part of Alector’s 2022 Inducement Equity Incentive Plan. The stock options will vest over four years, while the RSUs will vest over three years.
Alector, Inc. (Nasdaq: ALEC) reported positive safety and biomarker data from its first-in-human Phase 1 study of AL101, aimed at increasing progranulin (PGRN) levels for neurodegenerative diseases like Alzheimer’s and Parkinson’s. Conducted with 88 healthy volunteers, the trial demonstrated the drug's tolerability and ability to elevate PGRN in cerebrospinal fluid. Notably, multiple doses raised plasma PGRN levels to 160-200% above baseline. This data supports further exploration of AL101 for chronic conditions.
Alector, Inc. (NASDAQ: ALEC) reported its Q3 2022 financial results, revealing a significant decline in collaboration revenue to $14.9 million from $182.4 million YoY. The company continues to advance its clinical-stage pipeline, with ongoing enrollment in pivotal studies for latozinemab (AL001) and AL002 for Alzheimer’s disease, and has initiated a Phase 1 trial for AL044, targeting a key risk factor for the condition. With $758.3 million in cash and equivalents, Alector has sufficient runway through 2024 to support its ongoing research and development initiatives.
Alector, a clinical-stage biotechnology company based in South San Francisco, reported participation in two upcoming investor conferences. The events include the Guggenheim 4th Annual Immunology and Neurology Day on November 15, 2022, at 3:20 p.m. ET, and the Stifel 2022 Healthcare Conference on November 16, 2022, at 8:00 a.m. ET. Both presentations will be available via webcast on Alector's website, with replays accessible for 90 days post-event. Alector focuses on immuno-neurology and innate immuno-oncology, targeting neurodegenerative diseases through innovative therapeutic approaches.
Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology firm, announced on November 1, 2022, the grant of stock options and restricted stock units (RSUs) to five new employees under its 2022 Inducement Equity Incentive Plan. A total of 202,080 stock options and 101,039 RSUs were awarded, with an exercise price of $9.29 per share. The options vest over four years, while RSUs vest over three years. This grant aligns with Nasdaq Listing Rule 5635(c)(4) as a material inducement for employment, reflecting Alector's commitment to enhancing its workforce in immuno-neurology and immuno-oncology.
FAQ
What is the current stock price of Alector (ALEC)?
What is the market cap of Alector (ALEC)?
What is Alector, Inc. known for?
What are the main product candidates in Alector's pipeline?
What recent achievements has Alector accomplished?
Who are Alector's key collaborators?
What is the focus of Alector's immuno-neurology approach?
When is the data readout for the INVOKE-2 trial expected?
What is the Alector Brain Carrier (ABC) technology?
What financial condition is Alector currently in?
What is the significance of the FDA Breakthrough Therapy Designation for latozinemab?
Where can more information about Alector be found?
